Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  McManus, Hamish ^a   O'Connor, Catherine C ^b,c,d   Boyd, Mark ^a   Broom, Jennifer ^e   Russell, Darren ^f   Watson, Kerrie ^g   Roth, Norman ^h   Read, Phillip J ⁱ   Petoumenos, Kathy ^a   Law, Matthew G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e NAMBOUR GENERAL HOSPITAL   (Australia)

^f Cairns Sexual Health Service   (Australia)

^g ALFRED HOSPITAL   (Australia)

^h Prahran Market Clinic   (Australia)

ⁱ Sydney Sexual Health Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HEPATITIS B SURFACE ANTIGEN;

ADULT; AGE; AGED; ARTICLE; AUSTRALIA; CD4 LYMPHOCYTE COUNT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PARAMETRIC TEST; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEX RATIO; TREATMENT DURATION; VIRUS LOAD;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PROGNOSIS; SEX FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84868702305     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048839     Document Type: Article

References (29)

1. Harrison KM, Song R, Zhang X, (2010) Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 53: 124-130.
2. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, et al. (2006) HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 368: 451-458.
3. Mahy M, Stover J, Stanecki K, Stoneburner R, Tassie JM, (2010) Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults. Sex Transm Infect 86 Suppl 2: ii67-71.
4. Hogg R, Lima V, Sterne JA, Grabar S, Battegay M, et al. (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293-299.
5. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F, (2010) Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 24: 1527-1535.
6. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, et al. (2007) Survival of persons with and without HIV infection in Denmark, 1995-2005. Annals of Internal Medicine 146: 87-95.
7. d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, et al. (2005) The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Archives of Internal Medicine 165: 416-423.
8. Denholm JT, Yong MK, Elliott JH, (2009) Long term management of people with HIV. Aust Fam Physician 38: 574-577.
9. Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, et al. (2011) Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). HIV Med 12: 412-421.
10. Lewden C, the Mortality Working Group of COHERE. Time with CD4 Cell Count above 500 cells.mm3 Allows HIV-Infected Men, but not Women, to Reach Similar Mortality Rates to Those of the General Population 2010; San Francisco.
11. Hughes R, Sterne J, Walsh J, Bansi L, Gilson R, et al. (2011) Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. HIV Med 12: 583-593.
12. Wright ST, Carr A, Woolley I, Giles M, Hoy J, et al. (2011) CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts. J Acquir Immune Defic Syndr 58: 72-79.
13. Li X, Margolick JB, Jamieson BD, Rinaldo CR, Phair JP, et al. (2011) CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 57: 421-428.
14. The Australian HIV Observational Database (2002) Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med 3: 28-36.
15. Falster K, Choi JY, Donovan B, Duncombe C, Mulhall B, et al. (2009) AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS 23: 2323-2336.
16. Kowalska JD, Friis-Moller N, Kirk O, Bannister W, Mocroft A, et al. (2011) The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology 22: 516-523.
17. (2010) Table 1.9 Deaths, Summary, Australia-1999 to 2009. Australian Bureau of Statistics.
18. (2011) Table 59. Estimated Resident Population By Single Year Of Age, Australia. Australian Bureau of Statistics.
19. (2011) Table 1: Life Tables Australia 2007-2009. Australian Bureau of Statistics.
20. Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, et al. (2005) The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 38: 174-179.
21. Baillargeon J, Borucki M, Black SA, Dunn K, (1999) Determinants of survival in HIV-positive patients. Int J STD AIDS 10: 22-27.
22. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, et al. (2007) HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 46: 72-77.
23. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ, (2010) Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes 59: 3216-3222.
24. Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF, et al. (2006) Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 49: 298-305.
25. Ouhoummane N, Abdous B, Emond V, Poirier P, (2009) Impact of diabetes and gender on survival after acute myocardial infarction in the Province of Quebec, Canada-a population-based study. Diabet Med 26: 609-616.
26. May M, Gompels M, Delpech V, Porter K, Post F, et al. (2011) Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 343: d6016.
27. (2011) National Health Survey: Summary of Results, 2007-2008, Table 1.3: Health risk factors: Age and sex, Proportion of persons. Australian Bureau of Statistics.
28. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, et al. (1998) Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 351: 543-549.
29. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, et al. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 337: 725-733.